

HYPOGLYCEMICS, INCRETIN ENHANCERS (DPP-4 inhibitors) PRIOR AUTHORIZATION FORM

Prior authorization guidelines for **Hypoglycemics, Incretin Mimetics/Enhancers** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	total # of pages: _____	
Name of office contact:		Prescriber name:	
Contact's phone number:		Specialty:	
LTC facility contact/phone:		State license #:	
		NPI:	MA Provider ID#:
BENEFICIARY INFORMATION		Street address:	
Beneficiary name:		Suite #:	City/state/zip:
Beneficiary ID#:	DOB:	Phone:	Fax:

CLINICAL INFORMATION

Preferred medication requested (clinical prior authorization required):	<input type="checkbox"/> Janumet tablet	<input type="checkbox"/> Jentadueto tablet	<input type="checkbox"/> Tradjenta tablet
	<input type="checkbox"/> Januvia tablet	<input type="checkbox"/> Jentadueto XR tablet	
Non-preferred medication requested:	<input type="checkbox"/> alogliptin tablet	<input type="checkbox"/> Janumet XR tablet	<input type="checkbox"/> Nesina tablet
	<input type="checkbox"/> alogliptin/metformin tablet	<input type="checkbox"/> Kazano tablet	<input type="checkbox"/> Onglyza tablet
	<input type="checkbox"/> alogliptin/pioglitazone tablet	<input type="checkbox"/> Kombiglyze XR tablet	<input type="checkbox"/> Oseni tablet
	<input type="checkbox"/> _____		
Strength:	Dose/directions:	Quantity:	Refills:
Diagnosis (<i>submit documentation</i>):		Dx code (<i>required</i>):	
1. Does the beneficiary have a diagnosis of type 2 diabetes?		<input type="checkbox"/> Yes – <i>Submit documentation of diagnosis.</i> <input type="checkbox"/> No – <i>Submit medical literature supporting the use of the requested medication for the beneficiary's diagnosis.</i>	
2. Does the beneficiary have a history of trial and failure, contraindication, or intolerance of maximum tolerated doses of metformin ?		<input type="checkbox"/> Yes <i>Submit documentation showing trial and failure of, or contraindication or intolerance to, metformin (including result of a recent HbA1c).</i> <input type="checkbox"/> No	
3. Requests for NON-PREFERRED agents only: Does the beneficiary have a history of trial and failure, contraindication, or intolerance of the preferred Incretin Enhancers (DPP-4 Inhibitors)? <i>Check all that apply.</i>		<input type="checkbox"/> Yes <i>Submit all supporting documentation of preferred agents tried and treatment outcomes, including contraindications or intolerances.</i> <input type="checkbox"/> No	
		<input type="checkbox"/> Janumet tablet <input type="checkbox"/> Jentadueto tablet <input type="checkbox"/> Tradjenta tablet <input type="checkbox"/> Januvia tablet <input type="checkbox"/> Jentadueto XR tablet	

PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION

Prescriber Signature:	Date:
-----------------------	-------

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.